Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.

作者
Xavier Paolettí,Liz-Anne Lewsley,Gennaro Daniele,Adrian Cook,Nozomu Yanaihara,Anna V. Tinker,Gunnar B. Kristensen,Petronella B. Ottevanger,Gerasimos Aravantinos,Ingrid Boere,Robert Fruscio,Anna K.L. Reyners,Éric Pujade-Lauraine,Andrea Harkin,Sandro Pignata,Tatsuo Kagimura,Stephen Welch,Eleni Karamouza,Rosalind Glasspool,GCIG meta-analysis group
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 5576-5576
标识
DOI:10.1200/jco.2018.36.15_suppl.5576
摘要

5576 Background: OS is considered the gold standard endpoint for controlled clinical trials but it requires extended follow-up (median OS > 40 months for first line therapy) and large sample sizes. Our objective was to evaluate whether PFS based on CA125 measurements confirmed by radiological exam or on combined GCIG criteria is a surrogate endpoint for OS in AOC. Methods: Using the meta-analytic approach on trials published after 2000, correlations between PFS and OS at the individual level, and between treatment effects on PFS and on OS at the trial level, were estimated using Kendall’ tau and copula bivariate (R2Copula) models respectively. Criteria for PFS surrogacy required R2Copula ≥ 0.80. Results: We analyzed IPD from 8,973 patients enrolled in 15 randomized first line trials of standard (n = 7), intensification (n = 5) and maintenance (n = 3) chemotherapies or targeted treatments. No heterogeneity in the treatment effects across trials was detected. High correlations were found at the individual level (tau = 0.69) but low correlation at the trial level (R2Copula = 0.03). Sub-group analyses led to similar results. Conclusions: This large IPD meta-analysis did not establish PFS as a surrogate endpoint for OS in first line treatment of AOC, but the analysis was limited by the narrow range of treatment effects observed and post study treatment. Additional trials are being collected that will enable us to refine the sub-groups analyses. Table of results Endpoint / Trial type Trials N (pts) taua R2Copulaa Overall 15 (8973) 0.69 0.03 CA125 confirmed by radiological exam 9 (5126) 0.67 0.16 GCIG criteria 4 (2548) 0.7 0.14 Carbo-Tax as control 9 (5807) 0.72 0.05 Standard or intensification 12 (7703) 0.71 0.10 Maintenance 3 (1270) 0.64 0.14 atau and R2 values range from 0 (no association) to 1 (perfect correlation).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
0323完成签到 ,获得积分10
1秒前
步六孤完成签到,获得积分10
1秒前
忧郁井完成签到,获得积分10
1秒前
bszh发布了新的文献求助10
2秒前
阿呷惹完成签到,获得积分10
2秒前
九又四分之三完成签到,获得积分10
3秒前
风中的嘉熙完成签到,获得积分10
3秒前
4秒前
小白完成签到,获得积分10
4秒前
忧虑的电话完成签到,获得积分10
4秒前
5秒前
福星完成签到,获得积分20
5秒前
清爽荣轩发布了新的文献求助10
5秒前
勤恳代云完成签到,获得积分10
5秒前
道明嗣完成签到 ,获得积分10
5秒前
5秒前
ZHG关闭了ZHG文献求助
6秒前
时生完成签到 ,获得积分10
6秒前
6秒前
6秒前
郑皓文发布了新的文献求助10
6秒前
淡人完成签到,获得积分10
6秒前
云边小卖部完成签到 ,获得积分10
6秒前
花誓lydia完成签到 ,获得积分10
7秒前
7秒前
7秒前
wyl完成签到,获得积分10
7秒前
不良人发布了新的文献求助10
7秒前
8秒前
8秒前
8秒前
Jeff_Lin完成签到,获得积分10
8秒前
小冯完成签到 ,获得积分10
8秒前
含糊的玲完成签到,获得积分10
9秒前
lee完成签到,获得积分10
9秒前
小怪兽发布了新的文献求助10
9秒前
小小完成签到 ,获得积分10
9秒前
传奇3应助白小雨采纳,获得10
9秒前
慕慕倾完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7739175
求助须知:如何正确求助?哪些是违规求助? 9288108
关于积分的说明 20187257
捐赠科研通 7317308
什么是DOI,文献DOI怎么找? 3306034
关于科研通互助平台的介绍 2458554
邀请新用户注册赠送积分活动 2315987